To the Editor The Viewpoint by Drs Mora and Manson1 in a recent issue of JAMA Internal Medicine recognizes that aspirin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) needs to be highly individualized to accurately balance benefits and risks. They suggest a practical approach to aid clinicians with calculating ASCVD and bleeding risk using an app for mobile devices to facilitate patient discussion and shared decision making.1 While this could facilitate the benefit-risk assessment, the lack of integration of the app with the electronic health record and need for extensive data input are barriers to use in a busy primary care practice.
Sperl-Hillen J, Margolis K, Crain L. Risk and Benefit Information and Use of Aspirin. JAMA Intern Med. 2017;177(2):291. doi:10.1001/jamainternmed.2016.7988
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.